Table 2.

Demographic Characteristics and Outcomes of Patients With mrCDI Who Received a FDX-TP Regimen: The SFI After the Most Effective Prior Treatment Is Compared With the SFI After FDX-TP

	Age, Years/Sex	No. of CDI Episodes	Prior Regimens	Additional Antimicrobial Exposure After the Last Prior Regimen	Longest SFI for Non-FDX-TP Course, Days (Antibiotic)	SFI Post FDX-TP, Days	Recurrence After FDX-TP	Additional Antimicrobial Exposure After FDX-TP Regimens
Patient 4	68/F	5	M, M, VT, V + FDX-CH, FDX	None	64 (VT)	232	No	None
Patient 5	46/F	11	M, V, V, VT, V + FMT, V, RC, VT, VT, VT + FDX-CH, FDX	None	102 (V)	462	No	None
Patient 9	46/F	3	VT, FDX, FDX	None	29 (FDX)	571	No	None
Patient 10	65/M	4	U, M + V, VT, VT	None	21 (V)	429	No	None
Patient 11	37/F	4	M, M, VT, V + FDX	None	15 (M)	375	No	None
Patient 12	54/F	4	M, V, VT	None	35 (V)	298	No	None
Patient 13	68/F	3	M, VT, VT	None	8 (M)	121	No	None
Patient 14	70/F	4	VT, VT, VT, VT	None	81 (VT)	79	No	None
Patient 15*	86/M	8,9	M,M,V,V,VT,V,VT,VT + FDX-TP,VT	None, Amoxicillin	41 (V)	282	Yes, No	Yes
Patient 16	67/M	5	M,M,VT,V,VT	None	17 (V)	118	Yes	Yes
Patient 17	66/M	6	U,M,M,V,VT, VT	None	20 (V)	0	N/A**	None
Patient 18	91/M	4	M,M + VT,VT, VT	None	9 (VT)	23	No	None
Mean ± SD:	63.6 ± 16	5.1 ± 2		Median (IQR)	25 (30)	257 (280)***

Abbreviations: CDI, Clostridium difficile infection; FDX, standard fidaxomicin treatment regimen; FDX-CH, fidaxomicin chaser; FDX-TP, fidaxomicin taper; FMT, fecal microbiota transplantation; IQR, interquartile range; IVIG, intravenous immunoglobulin; M, metronidazole; mrCDI, multiple recurrent CDI; N/A, not applicable; RC, rifaximin chaser; SD, standard deviation; SFI, symptom-free interval; U, unknown; V, standard vancomycin treatment course; VT, vancomycin taper.

* Patient was given 2 FDX-TP courses.

** Patient did not complete FDX-TP regimen.

*** P = .003 compared with non-FDX-TP SFI, Mann–Whitney U test.